中文

← All funding rounds

Boltz

Also known as Boltz PBC, Boltz, PBC

United StatesScience models and AI scientistsCambridge, Massachusetts, United StatesFounded 2025Private

A public benefit corporation started by MIT researchers who released the open Boltz-1, Boltz-2 and BoltzGen models for biomolecular structure, binding affinity and binder design. It keeps those open and sells its newer proprietary models, BoltzMol-1 and BoltzProt-1, to drugmakers and industrial companies through the Boltz Lab interface and an API, fine-tuning them on a partner's own data.

Disclosed total$138M
Rounds on record2
Latest round$110MSeries A · 2026-11-18
Last stated valuationNone stated
Investors named11
Research on record1highest level 4 · Tested in the physical world

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date20262027$28M$110MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Series A, 2026-11-18: the record then held 1 research entry, highest level 4. The first research entry is dated 2026-09-15; the highest level so far is 4 (Tested in the physical world).

Rounds and research, on one timeline

  1. 2026-11-18Series A
    Round

    $110M

    For: compute and data, meeting demand from its pharma and industrial partners, and a larger team

    Models and platformData generationHiring

    The company's post names Bessemer's Andrew Hedin and Byron Deeter as coming in with the round, says all existing investors took part again, and adds that other new investors are not listed. It states no valuation. Boltz says six of the world's 20 largest pharmaceutical companies use the platform and that molecular tokens processed for paying customers have grown 50-fold since June.

    Lead · Bessemer Venture PartnersGreycroftF-PrimeHummingbird VenturesBenchlingExisting investor · a16zExisting investor · Amplify PartnersExisting investor · Zetta Venture PartnersExisting investor · Obvious Ventures

    On the deal: Andrew Hedin (Partner; the announcement names them as coming in with the round, Bessemer Venture Partners); Byron Deeter (Partner; the announcement names them as coming in with the round, Bessemer Venture Partners)

    By this date the record held 1 research entry, highest level 4

  2. 2026-09-15
    Research

    Level 4 · Tested in the physical world

    Boltz picked 27 compounds for Werner helicase with BoltzMol-1, and three of them inhibited the enzyme in the micromolar range

    Novartis reached its clinical WRN inhibitor HRO761 through three screening campaigns of nearly 350,000 compounds that left one usable hit, and the chemistry around it is now crowded: Boltz counts 62 patent publications from 36 organisations sharing the candidate's core. Its own two hits are chemically unlike it, at 0.08 and 0.14 on a 0-to-1 similarity scale, while the nearest compound in the model's affinity training data sits at 0.365. That is what a buyer of these tools wants: a different starting point for one chemist, two days of computing and a week of assays.

  3. 2026-01-08Seed
    Round

    $28M

    For: the team, the Boltz Lab platform and its small-molecule and protein design agents

    Models and platformHiring

    The company's launch post of 8 January names the backers without calling any of them a lead, and lists Hugging Face CEO Clement Delangue among strategic angels. It was announced the same day as the Pfizer collaboration and the Boltz Lab beta.

    Zetta Venture PartnersAmplify Partnersa16zFactorial CapitalObvious VenturesClement Delangue

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.